cookie-law-info domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/clients/client129/web245/web/wp-includes/functions.php on line 6121
It’s the EMVS’s Birthday! The European Medicines Verification System’s third anniversaryExecutive summaryToday marks the third anniversary of the European Medicines Verification (“EMVS”) System Go-live. This unique system ensures patient safety by detecting falsified...
Háziorvosok is felírhatják a favipiravirt COVID-19-betegeknekAkadémikusok javaslatára Mit kell tudni a gyógyszerről és milyen esetekben alkalmazható? Erről nyilatkozott az mta.hu-nak Keserű György Miklós akadémikus, a Természettudományi Kutatóközpont Gyógyszerkémiai...
Koronavírus elleni gyógyszertgyártó üzemet adtak át PilisborosjenőnEredményes az Egészségipari Támogatási Program,Magyarország önellátóvá vált az orvosi maszkok gyártásában, a kórházi gumikesztyűk előállításában, most pedig a vírus elleni védekezéshez szükséges...
• Innovating on existing molecules in the form of repurposing,
reformulation and combination of therapies has the potential to deliver
timely and effective solutions to unmet medical needs. However, the
current European environment does not allow to fully exploit this
approach.
• Value Added Medicines can empower patients by putting their needs
at the center of therapy design, improving overall therapy outcomes.
• Three key enablers are needed in the EU to promote continuous and
sustainable innovation: a fit-for-purpose regulatory framework ensuring
predictability in early development, the recognition of innovation with
proportionate incentives and the definition and the recognition of added value.
Forrás: Medicines for Europe